Evidence map›Paper›PMID 35582409›Full record

ArticleAnnals of global health2022

Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013-2021).

Francesco Di Gennaro, Rossana Lattanzio, Giacomo Guido, Aurelia Ricciardi, Roberta Novara, Giulia Patti, Sergio Cotugno, Elda De Vita, Gaetano Brindicci, Michele Fabiano Mariano and 8 more

Open access · goldAbstract read
In one paragraph

Article in Annals of global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Francesco Di GennaroClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.ORCID 0000-0003-3453-5647
Rossana LattanzioClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Giacomo GuidoClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Aurelia RicciardiClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Roberta NovaraClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Giulia PattiClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Sergio CotugnoClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Elda De VitaClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Gaetano BrindicciClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Michele Fabiano MarianoClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Luigi RongaMicrobiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT.
Carmen Rita SantoroClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Federica RomanelliMicrobiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT.
Stefania StolfaMicrobiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT.
Roberta PapagniClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Davide Fiore BavaroClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Giusi De IacoClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
Annalisa SaracinoClinic of Infectious Diseases, University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, IT.
University of Bari Aldo Moro · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic has undone years of progress in providing essential TB services and controlling the TB burden. Italy, a low TB burden country, has an incidence of 7.1 cases per 100,000 people. To control the TB spreading in Italy is critical to investigate the characteristics of patients with the worst outcomes and the highest risk of adverse events related to antituberculosis therapy. Therefore, we conducted a large retrospective study in TB patients admitted to the Clinic of Infectious Diseases University of Bari, Italy, in order to describe the clinical presentation and the factors associated with adverse events and outcomes. Methods: We retrospectively evaluated the patients admitted to the Clinic of Infectious Diseases from January 2013 to 15 December 2021. We stratified our cohort into two groups: <65 years of age and ≥65 years in order to assess any differences between the two groups. Two logistic regression models were implemented considering the dependent variables as: (I) the adverse events; and (II) the unsuccessful treatments. Results: In total, 206 consecutive patients [60% (n = 124) M, median age 39 years, range 16-92] were diagnosed and admitted with TB at Clinic of Infectious Diseases. Of the whole sample, 151 (74%) were <65 years and 55 (26%) were ≥65. Statistically significant differences between the two groups were detected ( Conclusions: The pharmacological approach alone seems insufficient to treat and cure a disease whose ethiopathogenesis is not only due to the

Indexed as

COVID-19Tuberculosis, PulmonaryAdolescentAdultAgedAged, 80 and overAntitubercular AgentsDelayed DiagnosisHospitalsHumansMiddle AgedPandemicsReferral and ConsultationRetrospective StudiesYoung AdultAntitubercular Agents

Identifiers

PMID35582409
PMCPMC9053535
OpenAlexW4225682160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.